Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C
Open Access
- 25 November 2016
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 1-8
Abstract
This study investigates differences in depression and anxiety between patients with chronic hepatitis C who are treated with peginterferon alpha-2a (PegIFN-α-2a) plus ribavirin and those who are treated with peginterferon alpha-2b (PegIFN-α-2b) plus ribavirin. In this 24 week, non-randomized, observational, prospective study, 55 patients with chronic hepatitis C were treated with PegIFN-α-2a plus ribavirin (Group 1), and 26 patients were treated with PegIFN-α-2b plus ribavirin (Group 2). All patients underwent assessment using the Hospital Anxiety and Depression Scale (HADS) at the baseline and at weeks 4, 12 and 24. Patients with depression scores (HADS-D) ≥ 8 and anxiety scores (HADS-A) ≥ 8 were defined as having depression and anxiety, respectively. The factors that were associated with depression and anxiety during the 24 week antiviral treatment were determined. During the 24 week antiviral treatment, the proportion of patients with depression significantly increased over time in both groups (Group 1: p = 0.048; Group 2: p = 0.044). The proportion of patients with anxiety did not significantly change during the follow-up period in either group. Incidences of depression or anxiety did not differ significantly between Group 1 and Group 2. A history of alcohol use disorder was an independent predictor of depression at week 12 (p < 0.001) and week 24 (p < 0.001), and a poor virological response to treatment was associated with depression at week 24 (p = 0.029). Patients who had more physical comorbidities were more likely to suffer from anxiety at week 12 (p = 0.038). This study did not identify significant differences in depression or anxiety between in patients with chronic hepatitis C who underwent a 24 week antiviral treatment regimen with PegIFN-α-2a plus ribavirin and those who underwent a regiment with PegIFN-α-2b plus ribavirin. Future research with larger samples and a randomized, controlled design are required to verify the findings in this study. This clinical study has been registered at ClinicalTrials.gov. (Trial registration: NCT02943330 ).Keywords
Funding Information
- National Science Council (TW) (NSC 96-2314-B-182A-090-MY2)
This publication has 32 references indexed in Scilit:
- Neuropsychiatric and Psychosocial Issues of Patients With Hepatitis C Infection: A Selective Literature ReviewHepatitis Monthly, 2013
- Efficacy and Tolerability of Peginterferonα-2a and Peginterferonα-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled TrialsGastroenterology Research and Practice, 2013
- Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statementJournal of Hepatology, 2012
- Depression and Suicide Risk in Hemodialysis Patients With Chronic Renal FailurePsychosomatics, 2010
- Pegylated Interferons for the Treatment of Chronic Hepatitis CDrugs, 2010
- Improved cognitive function as a consequence of hepatitis C virus treatment*HIV Medicine, 2007
- Depression following pegylated interferon-alpha: Characteristics and vulnerabilityJournal of Psychosomatic Research, 2007
- Interferon-Induced Depression in Chronic Hepatitis C: A Review of Its Prevalence, Risk Factors, Biology, and Treatment ApproachesJournal of Clinical Gastroenterology, 2006
- Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factorsGeneral Hospital Psychiatry, 2005
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004